TechnologyPatent OppositionCompetitive Analysis

In the competitive field of Mixed Drugs, companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top opposing and opposed companies, and the most recent patents getting opposed. Stay informed on the latest developments in Mixed Drugs technology and learn how to protect your intellectual property.

Get Patent Opposition Report for Mixed Drugs

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Download Your Report Now

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the Mixed Drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the Mixed Drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Jul 24, 2025
Patent NumberTitleApplicantOpposition DateOpposition Name

Get alerts on new patent oppositions in the Mixed Drugs industry

EP4241849Uses For And Article Of Manufacture Including Her2 Dimerization Inhibitor PertuzumabF HOFFMANN LA ROCHEJun 18, 2025BRAND MURRAY FULLER
EP4241849Uses For And Article Of Manufacture Including Her2 Dimerization Inhibitor PertuzumabF HOFFMANN LA ROCHEJun 17, 2025LANYON OPPOSITIONS
EP4129270Modified Release Orally Administered Amino Acid FormulationsAPR APPLIED PHARMA RESEARCHJun 10, 2025MAIWALD
EP4065119Methods Of Treating Pulmonary Arterial HypertensionACTELION PHARMACEUTICALSJun 4, 2025TEVA PHARMACEUTICAL INDUSTRIES
EP4065119Methods Of Treating Pulmonary Arterial HypertensionACTELION PHARMACEUTICALSJun 3, 2025SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI
EP4014976Aprocitentan For Use In The Treatment Of Hypertension And Related Diseases In Combination With Angiotensin Converting Enzyme Inhibitor (Ace) Or Angiotensin Receptor Blocker (Arb)IDORSIA PHARMACEUTICALSMay 29, 2025ELKINGTON AND FIFE
EP4084779Compositions Of 1-(4-Bromo-5-(1-Ethyl-7-(Methylamino)-2-Oxo-1,2-Dihydro-1,6-Naphthyridin-3-Yl)-2-Fluorophenyl)-3-PhenylureaDECIPHERA PHARMACEUTICALSMay 28, 2025ALFRED E TIEFENBACHER
EP3815684Methods Of Reducing The Risk Of A Cardiovascular Event In A Subject On Statin TherapyAMARIN PHARMACEUTICALS IRELANDMay 9, 2025ELKINGTON AND FIFE
EP3638243Methods For Treating Myeloproliferative Neoplasm-Associated Myelofibrosis And AnemiaCELGENEMay 7, 2025MAIWALD
EP3638243Methods For Treating Myeloproliferative Neoplasm-Associated Myelofibrosis And AnemiaCELGENEMay 5, 2025WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBB

To stay ahead in the competitive Mixed Drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the Mixed Drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Jul 24, 2025
Patent NumberGrant DateTitleApplicantTotal Oppositions
EP2478907Apr 14, 2021Methods And Compositions For Treating CancerJANSSEN ONCOLOGY22
EP3626270Oct 11, 2023New UseNOVARTIS16
EP2493466Mar 10, 2021Novel Antitumoral Use Of CabazitaxelSANOFI MATURE13
EP2981255Sep 14, 2022Therapeutic Uses Of EmpagliflozinBOEHRINGER INGELHEIM10
EP2766040May 15, 2019Uses For And Article Of Manufacture Including Her2 Dimerization Inhibitor PertuzumabFHOFFMANN LA ROCHE9
EP3494972Dec 13, 2023Combinations Of Dolutegravir And Lamivudine For The Treaetment Of Hiv InfectionVIIV HEALTHCARE9
EP3038654Oct 30, 2019New UseNOVARTIS9
EP2350096Dec 11, 2019Methods Of Treating Hepatic EncephalopathySALIX PHARMACEUTICALS8
EP2928496Oct 9, 2019Crispr-Based Genome Modification And RegulationSIGMA ALDRICH8
EP2400950May 22, 2019Pharmaceutical Formulations Comprising 4-{(1R)-2- [(6-{2-[(2,6-Dichlorobenzyl)Oxy] Ethoxy}Hexyl)Amino]-1-Hydroxyethyl}-2- (Hydroxymethyl)PhenolGLAXO GROUP8